 CAMBRIDGE, Mass.--BUSINESS WIRE--Sage Therapeutics, Inc. Nasdaq:SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntingtons disease HD. Fast Track is a process designed to facilitate the development and review of ne 